More on Wedbush's GTx (GTXI) defense which is likely behind the stock's 9.2% premarket rally:...

|By:, SA News Editor

More on Wedbush's GTx (GTXI) defense which is likely behind the stock's 9.2% premarket rally: "It bears repeating that … comparisons across groups of kilogram weight changes or watt power measurements" are not endpoints in the Phase III study, but "response rate for physical function" is, and the Lancet publication shows a 61% response rate vs. 39% placebo rate. Analyst David Nierengarten also says the mean/ median distinction in "the journalist's" article "ignores the design of the Phase III studies." Wedbush thinks enobosarm will meet its co-primary endpoints. (previous)